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Background: Information is needed at all stages of the policy making process. The Health Survey for England (HSE)
is an annual cross-sectional health examination survey of the non-institutionalised general population in England. It
was originally set up to inform national policy making and monitoring by the Department of Health. This paper
examines how the nurse collected physical and biological measurement data from the HSE have been essential or
useful for identification of a health issue amenable to policy intervention; initiation, development or implementation
of a strategy; choice and monitoring of targets; or assessment and evaluation of policies.
Methods: Specific examples of use of HSE data were identified through interviews with senior members of staff at
the Department of Health and the Health and Social Care Information Centre. Policy documents mentioned by
interviewees were retrieved for review, and reference lists of associated policy documents checked. Systematic
searches of Chief Medical Officer Reports, Government ‘Command Papers’, and clinical guidance documents were
also undertaken.
Results: HSE examination data have been used at all stages of the policy making process. Data have been used to
identify an issue amenable to policy-intervention (e.g. quantifying prevalence of undiagnosed chronic kidney disease),
in strategy development (in models to inform chronic respiratory disease policy), for target setting and monitoring
(the 1992 blood pressure target) and in evaluation of health policy (the effect of the smoking ban on second hand
smoke exposure).
Conclusions: A health examination survey is a useful part of a national health information system.
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Reliable health data and statistics are necessary to under-
pin health policies, strategies, and their evaluation and
monitoring, as well as providing the basis for sound
health information for the general public. Health surveys
that recruit a representative sample of the population
are the most appropriate way of collecting data on
health determinants, morbidity, and unmet health need
for use by national policy-makers. Health interview sur-
veys collect data through interview or self-administered* Correspondence: o.oyebode@ucl.ac.uk
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article, unless otherwise stated.questionnaires, while health examination surveys involve
taking some physical and/or biological measurements to
complement self-reported data.
The National Health Survey undertaken in the USA
in 1935 and 1936 was the first large survey examining
health status. Its aim was to study the extent and nature of
disability in the general population, particularly chronic dis-
ease and physical impairment [1]. It became the main data
source contributing to the government’s health proposals [1].
Since then the National Health and Nutrition Examination
Survey (NHANES) has run intermittently since the 1960s
and on a rolling basis since 1999; anecdotal evidence links
this survey to many health policy decisions [2].d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Oyebode and Mindell Archives of Public Health 2014, 72:24 Page 2 of 9
http://www.archpublichealth.com/content/72/1/24Seven European countries as well as South Korea, Japan,
Mexico and Australia, have conducted more than one
health examination survey [3,4]. Finland has the longest
running health examination survey in Europe, conducted
every 5 years since 1972. Other health examination surveys
have been conducted around the world; however most of
these have happened just once. Some countries are plan-
ning their first health examination survey and others are
seeking justification to fund one [5].
The Health Survey for England (HSE) is an annual
health examination survey which started in England in
1991 [6] and resulted from a 1988 ‘Command paper’, Pub-
lic Health in England [7]. (In the UK, command papers are
reports presented to parliament, as a statement of govern-
ment policy on a specific subject). At the time the HSE
was set up, several sources reported a lack of morbidity
data needed to measure and monitor the health of the UK
population [8,9].
The HSE samples a nationally representative random
cross-section of the free-living general population of
England. Following an advance letter to the selected
households, an interviewer visits to recruit up to ten
adults and up to two children per household. The inter-
viewer collects socio-economic data and information on
health and health-related behaviours, and measures
height and weight. Participants who agree are then vis-
ited by an experienced, trained nurse who takes physical
measurements, such as waist and hip circumferences and
blood pressure, and collects biological samples (i.e. blood,
urine and/or saliva) and information on medication use.
Field-staff undergo training, with refresher training annu-
ally. Data on adults has been collected yearly since 1991
and on children from 1995 onwards. In addition to an an-
nual published report, data are available through the UK
Data Service and are provided to the Department (Minis-
try) of Health directly [6].
Many measurements and samples have been taken
by the HSE nurses since 1991 (Table 1). These measure-
ments are essential to identify public health relevant
health indicators where other survey methods, such as
self-report, may not be reliable for prevalence estimation
[10-13]. In order to select measures and samples in-
cluded in the survey each year, each individual policy
team within the Department of Health considers what
its priorities and information needs are. If questions and/
or measurements from the HSE would be particularly useful
for up-coming policy development, they put a proposal to
Health and Social Care Information Centre (HSCIC) which
is discussed and costed. Where a policy team can fund this
from their budget and receives approval from senior fi-
nance officers, the information is collected.
There are many stages of policy making: from identify-
ing, quantifying and promoting recognition of health is-
sues to seek or to justify policy intervention; throughstrategy development, including economic analysis, im-
pact assessment, selection of targets; to target monitor-
ing and policy evaluation. This paper reviews use of HSE
examination data collected at the nurse visit, at each
policy stage. Specific examples are presented. There is
no previously published analysis of the use of health
examination data for policy making and monitoring,
however this work complements our examination of the
use of measured heights and weights in obesity policy,
presented elsewhere [10].
Methods
Specific examples of use of HSE data were identified
through interviews with 18 senior members of staff at the
Department of Health and at the HSCIC, both having re-
sponsibilities for England. Three of these interviewees
were former staff from the Department of Health. Initial
key informants were purposively sampled for their ex-
perience of working with HSE data; ‘snowball’ sampling
strategies were used to reach additional staff. Interviews
took place between May and July 2012.
Policy documents referred to by interviewees were
retrieved for review, and reference lists of associated policy
documents were checked. Systematic searches of Chief
Medical Office reports, command papers, and clinical guid-
ance documents were also undertaken. These documents
were read, looking for use of HSE data in the text, tables
or figures, or for the HSE in the reference list. A table was
compiled (Additional file 1: Table S1) and was shown to
interviewees to enable them to comment on whether any
important examples had been forgotten. Specific examples
are presented below, all other uses identified are outlined in
Additional file 1: Table S1.
Results
Identifying an issue amenable to policy intervention
Chronic Kidney Disease (CKD) is associated with serious
consequences including end-stage renal disease and car-
diovascular diseases. By identifying CKD, it is possible to
reduce the risk of these outcomes through preventative
treatment [14]. Measurement of the national kidney disease
burden is necessary to understand disease trends and aid
the development of evidence-based policy [14].
In 2009 and 2010, serum creatinine and urinary albumin
were collected as part of the HSE and used to calculate
survey participants’ estimated glomerular filtration rates
(eGFR) and the presence of albuminuria, respectively.
These clinical markers of CKD were used to derive the
overall prevalence of CKD in England, as well as preva-
lence by age, sex and socioeconomic status.
Before HSE data existed, prevalence of CKD in England
was estimated using serum creatinine measures recorded
on primary care computer systems, first as examined
by researchers [15], and since 2006, through the Quality
Table 1 Measurements and samples taken as part of the HSE, by year
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Measurements
Blood pressure 5+ • • • • • • •3 • • • • • • • • • •8 • • •
Demi span • • • • •3 •2 • •2 •2 •2 •6
ECG •3 •1
Grip strength •2
Physical function – balance •2
Lung function 7+ • • • •3 • • • •
Infant length • • • • • • •
Step test •7
Upper arm circumference • • • • •3
Waist/hip circumference 11+ • • • • •3 •2 • • • • • • • • • • • •
Walking speed •2
Blood sample
C reactive protein • •3 • • • •
Cotinine • • • •
Creatinine • •
Fibrinogen • • • •3 •1 • • •2 • •
Influenza antibodies •
Gamma gt • •
Glycated haemoglobin • • •3 •1 • • •2 • • • • • •
Haemoglobin + ferritin • • • • • • •3 •1 • • • •2 • •
HDL cholesterol • •3 •1 • • •2 • • • • • •
IgE/HDM Ige • • • •3 • • •
MCV •1 •2
Serum albumin •2 •2
Serum transferin •2
Total cholesterol • • • •3 •1 • • •2 • • • • •
Vitamin D •2 •2 •
Vitamin B12 •2
Fasting blood sample
Glucose •3 • •





















Table 1 Measurements and samples taken as part of the HSE, by year (Continued)
Triglycerides •3 • •
Saliva sample
Cotinine • • • •3 •4 •4 •4 •4 •4 •4 •5 •5 •5 •5 •5 •4
Urine sample 16+
Sodium, potassium, creatinine • • • • • • • •
Albumin • •
Melatonin •
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ports the calculation of practice-based performance pay-
ments to primary care practices (general practitioners,
GPs) in England. QMAS reported that the prevalence of
CKD in England was 4.3% in 2009–10 [16].
Relying on primary care data is not ideal for several rea-
sons. First, it is known that GP registers overstate the true
number of registered patients (known as GP list inflation),
for example because of the delay in updating lists when
patients move to a different practice or die [17]. This
increases the denominator, thereby decreasing the ap-
parent prevalence. Secondly, there are people living in
England who are not registered with any GP; if these
people have CKD, they would be missing from the nu-
merator as well as the denominator. Thirdly, there may
be under-recording by GP practices of diagnosed CKD
in their patients due to time constraints or IT failure.
Finally, and most importantly, there are patients with
CKD who are registered with a GP but who have not been
tested for, and therefore do not have a diagnosis of, CKD.
Based on eGFR data from the HSE 2009 and 2010, it is
estimated that 6% of men and 7% of women have stage 3–
5 CKD [11]. The difference between these figures and
those from QMAS suggests that one-third of people with
CKD in England are not represented in the QMAS figures
and this could mean that a third of people with CKD are
not diagnosed.
Further to this, each year that CKD prevalence has been
reported through QMAS, prevalence has increased - from
3.0% in 2006–07, to 3.7% in 2007–08, 4.1% in 2008–09
and 4.3% in 2009–10. This is evidence that CKD ascer-
tainment is increasing in GP surgeries, but does not
distinguish between an increase in prevalence and an
increase in diagnosis. The kidney team at the Department
of Health were able to commit funding to examine stored
blood samples collected from HSE participants in 2003–
05 to produce trend data for the population prevalence of
CKD from 2003–05 to 2009–10. Department of Health
staff stated that whether the trend is going up or down,
this information will feed into future policy work.
The HSE CKD prevalence data have influenced
National Institute for Health and Care Excellence
(NICE) guidance on CKD, including quality standards
and commissioning of services, as well as being cited
amongst reasons for reviewing clinical guidance [18-20].
They have been used in calculation of the financial costs
of CKD, producing figures that help urge policy action to
prevent CKD [21,22]. The HSE data have also been used to
model prevalence at the local level to drive local action on
CKD [23].
These examples demonstrate how accurate prevalence
data, collected through the HSE, has been used to advocate
for CKD at a policy level. Other specific examples of using
HSE examination data to identify, quantify or highlight anissue amenable to policy intervention are shown in Add-
itional file 1: Table S1. These include insight into the preva-
lence of undiagnosed hypertension, Chronic Obstructive
Pulmonary Disease (COPD) and diabetes; examination of
the prevalence and risk factors for vitamin D deficiency,
iron deficiency anaemia, physical inactivity, raised dust-
mite specific IgE and raised cholesterol; and presentation
of cotinine data to support policy action on second-hand
tobacco smoke.Strategy development
As with the CKD example above, clinical markers for
COPD, specifically lung function tests, have been exam-
ined in HSE participants in eight of the past 20 years,
allowing population prevalence to be examined and
compared with the prevalence of diagnosed COPD in
primary care data. HSE 2001 data have been used to
model estimated COPD prevalence in the UK [24-26]. Sha-
hab et al’s study modelled the HSE 2001 spirometry data
categorised using the joint American Thoracic Society
(ATS) and European Respiratory Society (ERS) guidelines.
Their results were used by the British Lung Foundation to
estimate that there were 3.7million cases of COPD in the
UK [27]. However, primary care data showed only 900,000
diagnosed cases at that time. The British Lung Foundation
therefore launched a campaign to find the ‘missing millions’
– the 2.8 million people in Britain with undiagnosed COPD
- so that they could receive treatment (both medication and
lifestyle advice, particularly support for smoking cessation)
to reduce the individual and national burden of morbidity,
disability, and premature mortality [27].
HSE data were also used in the development of the
Department of Health strategy for COPD. The Outcomes
Strategy for COPD and Asthma examined the prevalence
of undiagnosed COPD and the ratio of diagnosed to ex-
pected prevalence of COPD by geographical area, citing
studies which used HSE lung function data [28]. HSE
COPD data were used in models that were used to fulfil
the UK legal requirement to consider the effect of all gov-
ernment strategy on nine ‘protected characteristics’:
age, disability, gender reassignment, marriage and civil
partnership, pregnancy and maternity, race, religion or
belief, sex, and sexual orientation. Interviewees told us
that COPD data were further used in strategy implemen-
tation, making the case for the COPD outcomes strat-
egy with healthcare professionals, and encouraging their
acceptance of its recommendations.
Lastly, clinical guidance development has also used the
COPD data collected by the HSE. A cost-effectiveness
model comparing treatment with combinations of long-
acting-beta-agonists, long-acting muscarinic antagonist
and inhaled corticosteroids in people with severe/very
severe COPD used Health Survey for England data to set
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agnosed with COPD in England [29].
Specific ways that HSE examination data have been used
in strategy development in other disease areas are shown in
Additional file 1: Table S1. These include the use of hyper-
tension, glycated haemoglobin and cholesterol data in the
economic modelling for vascular checks; and urinary albu-
min and creatinine data supporting the calculation of the
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Figure 1 Changes in systolic blood pressure over time. Health
of the Nation target: To reduce mean systolic blood pressure in the
adult population by at least 5 mmHg by 2005 from the 1994
baseline. a) Men b) Women.Target setting and monitoring
Like the HSE, the Health of the Nation strategy resulted
from recommendations made in the 1988 command
paper, Public Health in England. The Health of the Na-
tion 1992 was the first attempt by a UK government to
take a strategic view of health [30]. A range of targets to
measure improvement in the population’s health were
set in the Health of the Nation; the newly commissioned
HSE was one way in which targets would be monitored,
where existing health information was lacking. One such
information need was data on which to base a blood
pressure target. For this reason, the 1992 blood pressure
target stated “baseline to be derived from new national
health survey”. Once this data had been collected, the
target became “To reduce mean systolic blood pressure in
the adult population by at least 5mm Hg by 2005”.
Monitoring of this target was to be done using HSE
data [31].
When this target was set, the detection and management
of hypertension was typically characterised by the ‘rule of
halves’: 50% of cases have been diagnosed, of which 50%
are treated, and 50% of those are controlled [32]. A number
of government policies were introduced in England to im-
prove this, including the Quality and Outcomes Framework
[33] for GPs introduced in 2004, which provided finan-
cial incentives to measure blood pressure and treat
hypertension adequately [33]. Studies using HSE data
from 1998, 2003, and 2006 showed that awareness of
hypertension rose in men between 1998 (40% of those
with ‘survey-defined hypertension’ (i.e. a systolic blood
pressure of ≥ 140 mmHg, a diastolic blood pressure of ≥
90 mmHg, or taking medication for hypertension)) and
2003 (60%) but changed little thereafter (62% in 2006),
while in women it rose from 58% in 1998 to 64% in
2003 and to 71% in 2006. The proportion on treatment
had risen in both sexes, from 33% in 1998 to 54% in 2006
in men and 44% to 62% respectively in women. Control of
blood pressure levels had also risen, from 13% to 26% of
men and 16% to 32% in women with hypertension over
these eight years; among those reporting antihypertensive
medication, it rose from 48% in 2003 to 52% in 2006 in
men and from 44% to 53% respectively in women [34,35].
Further improvements were apparent by 2011, with 63% ofmen and 61% of women on antihypertensive treatment
having controlled blood pressure [12].
Assessment of population systolic blood pressure,
using measurements undertaken by the HSE nurses,
shows that this target was achieved ahead of time
(Figure 1).
Other targets set and/or monitored using HSE examin-
ation data are shown in Additional file 1: Table S1. The
hypertension data has been used to monitor inequality,
through an indicator developed by the WHO. Cotinine
measures from children have been used to monitor the pro-
portion of homes where both parents are smokers but
where the home itself has been declared smoke free.
Evaluation and review of policies
Passive smoking has been assessed in the HSE through
cotinine, in blood in earlier years and in saliva since the
mid-1990s. The smoke free law, which banned smoking
in work and public places, was passed as part of the
2006 Health Bill and came into force on 1st July 2007 in
England. The primary aim was to decrease the exposure
of non-smoking adults to tobacco smoke, particularly
Oyebode and Mindell Archives of Public Health 2014, 72:24 Page 7 of 9
http://www.archpublichealth.com/content/72/1/24those working in the hospitality industry, where clients’
smoke was responsible for high levels of environmental
tobacco smoke.
Data from salivary cotinine in non-smoking adults,
collected by the Health Survey, demonstrates that these
intended consequences of the smoking ban occurred as
expected [36,37], with a marked decrease in mean saliv-
ary cotinine in non-smoking adults and an increase in
the number with no detectable cotinine. This provides
some evidence of policy success.
However, prior to the legislation being passed, de-
tractors of the proposed smoke free law postulated that
adults who had previously smoked in public places
would instead be smoking in their homes. A displace-
ment of their smoking activity from one arena to an-
other could mean an increase in environmental tobacco
smoke in locations where children are more likely to be
present [38]. This would then have unintended conse-
quences for the health of children and young people.
Fortunately, HSE data showed that this was not the case,
with children aged 4–15 significantly more likely to have
undetectable cotinine in 2008 compared with 2006 [39].
Other ways in which HSE data have been used in policy
evaluation and review are shown in Additional file 1: Table
S1. Hypertension data have been used in several ways for
policy evaluation and review, includes reviewing guide-
lines for the treatment of hypertension, the contribution
of various health policies to CVD mortality in England
(for which diabetes and cholesterol data were also used);
and in examination of the association between primary
care doctor numbers and the presence of undiagnosed
cardiovascular disease. Cholesterol data were also used
when examining the effects of the introduction of pay-by-
performance for primary care and in reviewing the effects
of allowing statins to be dispensed over-the-counter (with-
out a prescription from a doctor). Examination of older
people’s walking speeds had implications for the Mayor of
London’s traffic calming strategy- in which the time given
for pedestrians to cross the road would be reduced.
Discussion
This paper presents specific examples of how the HSE
examination data have been used by policy-makers. This
includes identifying an issue amenable to policy-
intervention, for example highlighting the greater
prevalence of CKD overall than assumed from health-
care data. Measuring this problem raised the profile of
CKD, allowing the context to be set for an increased drive
for diagnosis and preventative action. HSE data have also
been used in strategy development, with COPD preva-
lence data feeding in to development and implementa-
tion of government strategy and modelling for clinical
guidance. HSE has been used in setting and monitoring
targets, as for the 1992 Health of the Nation bloodpressure targets; and in evaluation and review of health
policy, for example examining the effects of the smoking
ban on passive smoking by adults and children.
Some of the results cited in policy documents were
from the official HSE reports, however there were also
citations of peer-reviewed papers of secondary analyses
of HSE data published in academic journals. Some policy
documents used in-house analysis of the HSE data.
Previous studies examining the accuracy of self-reported
health in comparison with health examination data have
shown that for many health outcomes, self-reported results
are inaccurate [10-13]. For example self-reported hyperten-
sion tends to be underestimated, so results from examin-
ation in a population survey may give more than twice the
prevalence of hypertension than that found from an inter-
view survey. Although comparison of self-reported diagno-
sis with medical records shows that the former is reasonably
accurate, disease prevalence is generally under-reported
compared with health examination studies, due to under-
diagnosis. This is particularly true for hypertension and
CKD e.g: [11,12]. Hypercholesterolaemia, diabetes, osteo-
arthritis and coronary heart disease are also underestimated
by self-report, [13], as is obesity prevalence [10].
It was not possible to review all health policy documents
for this study. In addition, policy making is a complex
process and not all the sources that have fed into decision
making are formally documented in final published docu-
ments. In interviews held as part of this work, a senior
member of staff from the Department of Health said that
often the influence of the HSE on pieces of policy work
are indirect and unacknowledged. For example, it may be
that a minister believes something which the data shows
to be false. In this instance, a minister may accept the
findings and adjust what they say from that point on,
without any formal or public reference to what has af-
fected their new position. That interviewee, and others,
told OO that data can be absorbed into the conscious-
ness and contribute to the thinking in the Department
of Health without leading directly to a policy. Thus this
paper has underestimated the ways in which the HSE has
influenced health policy in the UK, with some in-
stances not identified.
There are measurements which appear to have been
used (at least explicitly) to a greater degree than others.
Blood pressure and cotinine measurements were most
frequently cited in the policy documents identified.
There are also measurements that have been taken as
part of the HSE for which we were unable to identify pol-
icy uses so far. These are measured C-reactive protein, fi-
brinogen, ‘flu antibodies, and gamma gt from blood;
measured melatonin from the urine sample; and ECG
data. Some of these measurements are very new and may
not yet have had a chance to affect published policy docu-
ments. However, there was one example found of a missed
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had not been located [40]. There were other examples of
non-use, for example in the Standing Advisory Committee
on Nutrition (SACN) 2010 Iron and Health report, which
stated that HSE did not have specific data on iron defi-
ciency anaemia, when in fact this had been collected.
Qualitative work with Department of Health staff has
provided some reasons for under-use of HSE data.
Conclusions
There is much anecdotal evidence that health examination
surveys are valued by policy makers [2]. When the UK
Secretary of State for Health was asked in Parliament what
benefits have resulted from funding and carrying out the
HSE, the response was that HSE is a major vehicle, pro-
viding valuable annual data about the nation's health and
the information is used to underpin strategies for promot-
ing better health [41]. However, until now there has not
be documented evidence of specific examples in which
policy was shaped by collection of health examination data
through the HSE. This paper shows the ways in which a
health examination survey can contribute to national
health policy, demonstrating that is it a useful part of a na-
tional health information system.
Additional file
Additional file 1: Table S1. Specific examples of HSE examination data
used in policy making and monitoring.
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